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Abstract
Background: Due to the limited RNA amounts from endomyocardial biopsies (EMBs) and low
expression levels of certain genes, gene expression analyses by conventional real-time RT-PCR are
restrained in EMBs. We applied two preamplification techniques, the TaqMan® PreAmp Master Mix
(T-PreAmp) and a multiplex preamplification following a sequence specific reverse transcription
(SSRT-PreAmp).
Results: T-PreAmp encompassing 92 gene assays with 14 cycles resulted in a mean improvement
of 7.24 ± 0.33 Ct values. The coefficients for inter- (1.89 ± 0.48%) and intra-assay variation (0.85 ±
0.45%) were low for all gene assays tested (<4%). The PreAmp uniformity values related to the
reference gene CDKN1B for 91 of the investigated gene assays (except for CD56) were -0.38 ±
0.33, without significant differences between self-designed and ABI inventoried Taqman® gene
assays. Only two of the tested Taqman® ABI inventoried gene assays (HPRT-ABI and CD56) did
not maintain PreAmp uniformity levels between -1.5 and +1.5. In comparison, the SSRT-PreAmp
tested on 8 self-designed gene assays yielded higher Ct improvement (9.76 ± 2.45), however was
not as robust regarding the maintenance of PreAmp uniformity related to HPRT-CCM (-3.29 ±
2.40; p < 0.0001), and demonstrated comparable intra-assay CVs (1.47 ± 0.74), albeit higher inter-
assay CVs (5.38 ± 2.06; p = 0.01). Comparing EMBs from each 10 patients with dilated
cardiomyopathy (DCM) and inflammatory cardiomyopathy (DCMi), T-PreAmp real-time RT-PCR
analyses revealed differential regulation regarding 27 (30%) of the investigated 90 genes related to
both HPRT-CCM and CDKN1B. Ct values of HPRT and CDKN1B did not differ in equal RNA
amounts from explanted DCM and donor hearts.
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Conclusion: In comparison to the SSRT-PreAmp, T-PreAmp enables a relatively simple workflow,
and results in a robust PreAmp of multiple target genes (at least 92 gene assays as tested here) by
a mean Ct improvement around 7 cycles, and in a lower inter-assay variance in RNA derived from
EMBs. Preliminary analyses comparing EMBs from DCM and DCMi patients, revealing differential
regulation regarding 30% of the investigated genes, confirm that T-PreAmp is a suitable tool to
perform gene expression analyses in EMBs, expanding gene expression investigations with the
limited RNA/cDNA amounts derived from EMBs. CDKN1B, in addition to its function as a
reference gene for the calculation of PreAmp uniformity, might serve as a suitable housekeeping
gene for real-time RT-PCR analyses of myocardial tissues.
Background
Dilated cardiomyopathy (DCM) is a heterogeneous dis-
ease of multifactorial etiopathogenesis. However, investi-
gations on endomyocardial biopsies (EMBs) have
revealed that chronic T-cell infiltration (inflammatory car-
diomyopathy/DCMi), induced and maintained by cardio-
tropic viral infections, as well as by secondary
autoimmune pathways, is identifiable in a significant pro-
portion of patients presenting with DCM [1-6]. In addi-
tion, functional characterization of infiltrates and
expression investigations of further immunocompetent
factors may be decisively important for a profound under-
standing of the pathogenesis of DCMi, as well as for
immunomodulatory treatment strategies [5,7-13]. Fur-
thermore, expression of genes involved in general heart
failure pathways such as the remodeling of the extracellu-
lar matrix is altered in EMBs from DCM patients [14].
Gene expression investigations of EMBs are promising
approaches for the investigation novel pathogenic path-
ways involved in DCM/DCMi [15], and may reveal pro-
files with prognostic impact for the natural course of the
disease as well as under immunomodulatory treatment
[4,11-13,16].
Real-time RT-PCR is a sensitive, precise and reproducible
tool to determine gene expression in tissues. However, the
RNA amounts extractable from EMBs are low, thereby
limiting the number of analyzable target genes by real-
time RT-PCR. Preamplification (PreAmp) techniques may
enhance sensitivity of real-time RT-PCR especially for low
abundance genes, and can establish substantially higher
cDNA amounts, which can then expand the number of
the analyzable target genes. However, maintenance of
gene expression profiles as well as a broad applicability to
many target genes with a feasible additional effort is a fur-
ther intriguing aspect of PreAmp procedures.
We here report the application of the TaqMan® PreAmp
Master Mix technique (T-PreAmp) to EMBs' cDNA, which,
as in PBMCs' cDNA, enables a robust PreAmp of multiple
pooled TaqMan® ABI inventoried gene expression assays
and primers of self-designed gene expression assays,
including wobbled primer designs, with acceptable
PreAmp uniformity values (except for 2 of the investigated
gene assays), and low intra- and inter-assay variance coef-
ficients. We compared this technique with a sequence-
specific reverse transcription (SSRT) technique followed
by a multiplex PreAmp step (SSRT-PreAmp) in accordance
to the strategy by Peixoto et al. [17] in a set of self-
designed 7 gene assays for T-cell specific genes, which per-
formed with a partly higher PreAmp efficacy (improve-
ment of Ct values), however resulted in substantial
variations of PreAmp uniformity, and higher inter-assay
variation coefficients (CVs), and moreover did not offer
the possibility of expanding the possible real-time RT-PCR
analyses out of the limited EMBs' cDNA. Furthermore, we
show preliminary data on the differential expression of 27
out of 90 (30%) investigated target genes in patients with
EMBs-confirmed DCMi compared with EMBs from DCM
patients. Moreover, we provide evidence that CDKN1B
(cyclin-dependent kinase inhibitor 1B) as well as HPRT
(hypoxanthine-guanine phosphoribosyltransferase) is
not differentially expressed in DCM versus donor hearts,
and may therefore be a relevant housekeeping gene candi-
date for real-time RT-PCR analyses of myocardial tissues.
Results
PreAmp real-time RT-PCR from PBMCs' cDNA
T-PreAmp
Albeit the Ct values obtained from cDNA from both
PBMCs and EMBs in conventional direct real-time PCR
were virtually equivalent (difference around 0.3 Ct val-
ues) with respect to the hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) gene assay designed by the
Institute of Medical Immunology at the Charité-Campus
Mitte (HPRT-CCM) and the ABI inventoried Taqman®
gene assay for HPRT (HPRT-ABI) in initial investigations,
T-PreAmp cDNA revealed differences in PreAmp uniform-
ity values of these two HPRT gene assays. Whereas the Ct
improvement for HPRT-CCM was 7.2, the gene assay
HPRT-ABI achieved a Ct improvement of only 4.9 cycles.
This resulted in a PreAmp uniformity related to CDKN1B
of 0.82 for HPRT-CCM and 3.14 for HPRT-ABI, respec-
tively. In light of this minor T-PreAmp performance of the
HPRT-ABI gene assay, we used further on only the HPRT-
CCM as housekeeping gene assay. Direct real-time PCRBMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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from the pooled PBMCs' cDNA revealed a mean Ct value
31.28 ± 3.47 (range: 24.75 to 38.93), and in T-PreAmp
cDNA a mean Ct value of 23.91 ± 3.46 (range: 16.92 to
31.85) for the investigated gene assays excluding CD56. T-
PreAmp yielded a mean improvement of 7.37 ± 0.51
cycles (range: 6.35 to 8.90) for the investigated gene
assays (p < 0.0001 compared with the Ct values derived
from the direct real-time RT-PCR). There was no traceable
gene expression neither in the non-preamplified nor in
the T-PreAmp cDNA with respect to IL-5, IL-10, IL-17, IL-
27, IFN-b, CYR61, CXCL14, CX3CL1, APN, GRAIL, colla-
gen types I, III and IV, laminin, MMP3, TIMP-4, GDF15
and CD62E. Considering the threshold Ct for low expres-
sion levels published by Canales et al. [18], 13/78 (17%)
of the target genes showed Ct values ± 35 in direct real-
time RT-PCR. The mean PreAmp uniformity for the inves-
tigated gene assays in PBMCs (excluding CD56) related to
CDKN1B was 0.24 ± 0.50, ranging from -1.26 to 1.29, and
the PreAmp uniformity in PBMCs related to HPRT-CCM
was 0.39 ± 0.54, ranging from -1.06 to 1.49, respectively.
There was no significant difference between the self-
designed (mean Ct improvement: 7.46 ± 0.49 cycles;
PreAmp uniformity related to CDKN1B: 0.23 ± 0.47, and
related to HPRT-CCM: 0.34 ± 0.56, respectively) and the
Taqman® ABI inventoried gene assays (mean Ct improve-
ment: 7.38 ± 0.53 cycles; PreAmp uniformity related to
CDKN1B: 0.25 ± 0.53, and related to HPRT-CCM: 0.45 ±
0.52, respectively; p each >0.05; excluding CD56). With
respect to CD56, PreAmp uniformity related to CDKN1B
was 3.63, and 2.82 related to HPRT-CCM, respectively.
There was no association between the PreAmp uniformity
related to CDKN1B of target gene Ct values in direct real-
time RT-PCR < 35 (0.27 ± 0.43) or ≥ 35 (0.05 ± 0.78). The
same was true for the PreAmp uniformity values related to
HPRT-CCM (Ct < 35: 0.45 ± 0.46; Ct ≥ 35: 0.17 ± 0.86).
In light of the disproportionate PreAmp uniformities of
HPRT-CCM and HPRT-ABI, whilst yielding comparable
Ct values in conventional real-time RT-PCR, we hypothe-
sized that PCR efficiency during PreAmp might be a piv-
otal issue. The comparison of the two gene assays showing
minor PreAmp performance (HPRT-ABI and CD56) to
candidate (self-designed and Taqman® ABI inventoried)
gene assays with T-PreAmp uniformities ranging between
-1.5 and +1.5 (HPRT-CCM, CD3d, CD3z, TRBC, TRBV19,
TRBV29, NFATC3 and avb1) over serial dilutions of
PBMCs' cDNA revealed a non-significant tendency for
increased PCR efficiency by T-PreAmp (0.92 ± 0.04 versus
0.89 ± 0.05 by direct real-time RT-PCR; excluding CD56;
Figure 1a). This was also true for HPRT-ABI. PreAmp uni-
formity for these gene assays except for CD56 showed
comparable PreAmp uniformities over the serial cDNA
dilutions (Figure 1b). The CD56 gene assay, however,
demonstrated a substantially decreased PCR efficiency by
T-PreAmp compared with direct real-time RT-PCR (0.62
versus 1.03; Figure 1a), and a gradually increasing
PreAmp uniformity at serial cDNA dilutions to 8.37 at the
ratio 1:512 (no expression at 1:1,024; Figure 1b).
SSRT-PreAmp (sequence-specific reverse transcription 
followed by a multiplex PreAmp)
Using the SSRT-PreAmp system on HPRT-CCM as house-
keeping gene and further 7 T-cell related self-designed
gene assays, a mean improvement of 9.26 ± 1.94 cycles
(range: 7.09–11.9) was obtained. The measured Ct values
in direct real-time RT-PCR were 29.99 ± 3.84 (range:
24.18–37.36), and in SSRT-PreAmp 20.73 ± 3.81 (range:
16.40–28.53; p < 0.0001 compared with the Ct values
derived from the direct real-time RT-PCR). Considering
the threshold Ct for low expression levels published by
Canales et al. [18], 1/7 (14%) of the target genes showed
Ct values ≥ 35 in direct real-time RT-PCR. The mean
PreAmp uniformity for the investigated gene assays
related to HPRT-CCM was -2.49 ± 2.04 (range: -4.81–0),
which was significantly (p < 0.0001) lower compared
with the T-PreAmp data. The following gene assays were
below a PreAmp uniformity of -1.5: CD3z, IFNg, T-bet
and Perforin. There was no association between the
PreAmp uniformity related to HPRT-CCM of target gene
Ct values in direct real-time RT-PCR < 35 (-2.61 ± 0.9) or
≥ 35 (-1.75 ± 2.2).
PreAmp real-time RT-PCR from EMBs
T-PreAmp
T-PreAmp of EMBs' cDNA with the investigated target
gene assays resulted in a mean Ct improvement of 6.86 ±
0.13 (range: 6.65 – 7.07) for CDKN1B, and in mean
improvement of 7.16 ± 0.14 Ct values (range: 6.91 – 7.39;
p < 0.0001 compared with the Ct values derived from the
direct real-time RT-PCR) for HPRT-CCM, respectively. The
mean PreAmp uniformity for HPRT-CCM related to
CDKN1B was -0.30 ± 0.05 (range: -0.37 to -0.21). The
mean  ΔΔCt [PreAmp cDNA] – ΔCt [cDNA] for HPRT-
CCM and CDKN1B was 0.30 ± 0.05 (range: 0.22 to 0.37).
There was a high association between the Ct values of
HPRT-CCM and CDKN1B both in cDNA (Spearman ρ:
0.86, p < 0.0001) and in PreAmp cDNA (Spearman ρ:
0.83, p < 0.0001). Moreover, the ΔCt values of CDKN1B
and HPRT-CCM of [cDNA] versus [PreAmp cDNA]
showed a high correlation (Spearman ρ: 0.99, p <
0.0001). The inter-assay CVs were 1.85% for CDKN1B,
and 1.93% for HPRT-CCM, respectively.
With respect to the investigated target gene assays (except
for CD56), T-PreAmp yielded a mean improvement of
7.24 ± 0.33 Ct values (range: 6.31 to 7.84). The CD56
gene assay demonstrated a mean Ct improvement of 3.37
± 0.09. The PreAmp uniformity of the investigated gene
assays (except for CD56) related to CDKN1B was -0.38 ±
0.33 (range: -1.01 to 0.59; Figure 2), and related to HPRT-BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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CCM -0.08 ± 0.33, (range: -0.70 to 0.88; Figure 3), respec-
tively. As in cDNA from PBMCs, there was no significant
difference between the self-designed (mean Ct improve-
ment: 7.3 ± 0.27 Ct values; PreAmp uniformity related to
CDKN1B: -0.42 ± 0.29, and related to HPRT-CCM: -0.17
± 0.30, respectively) and the inventoried ABI gene assays
(mean Ct improvement: 7.20 ± 0.36; PreAmp uniformity
related to CDKN1B: -0.36 ± 0.36, and related to HPRT-
CCM: -0.06 ± 0.36, respectively; p each >0.05). Consider-
ing the threshold Ct for low expression levels published
by Canales et al [18], 48/337 (14%) of the target genes
showed Ct values ≥ 35 in direct real-time RT-PCR, whereas
Ct values for HPRT-CCM demonstrated <28, and for
CDKN1B < 26 in each case of the 4 investigated EMBs.
There was no association between the PreAmp uniformity
related to CDKN1B of Ct values below (-0.33 ± 0.6) or
above (-0.4 ± 0.34) the threshold Ct for low expression
levels (35). The same was true for the PreAmp uniformity
values related to HPRT-CCM (Ct < 35: -0.03 ± 0.6; Ct ≥ 35:
-0.1 ± 0.35). The inter-assay variance of Ct improvement
for the investigated gene assays preamplified in each 4 dif-
ferent EMBs was below 0.5 Ct values (Figure 4), and the
resulting mean CV was 1.89 ± 0.48% (range: 0.75 to
3.39), including the CD56 gene assay, which did not per-
form differently compared to the remaining gene assays in
this respect (Figure 5). ABI inventoried gene assays dem-
onstrated a higher inter-assay CV (1.99 ± 0.46%) com-
pared with the self-designed gene assays (1.74 ± 0.46%; p
= 0.0135). Noticeably, there was no traceable gene expres-
sion in some of the investigated each EMBs per gene group
with respect to TRBV7, 10, 14, 15, 16, 24, 25, 27, 28, IL2,
IL5, IL10, IFNb and APN neither in the direct nor in the
PreAmp real-time RT-PCR (Figure 4).
The 5 different PreAmp procedures from the cDNA from
1 EMB resulted in minor differences of Ct values (Figure
6). The mean intra-assay CV was 0.85 ± 0.45% (range:
0.19 to 2.58), including CD56, which did not perform dif-
PCR efficiency and PreAmp uniformity in PBMCs using T-PreAmp Figure 1
PCR efficiency and PreAmp uniformity in PBMCs using T-PreAmp. a) Comparison of PCR efficiency of the investi-
gated candidate gene assays calculated from PBMCs' cDNA (25 ng/μl) and 7 dilution steps (up to 1:1,024) by direct (cDNA) 
and T-PreAmp real-time RT-PCR (T-PreAmp). Taqman® ABI inventoried gene assays are indicated by red bars, self-designed 
gene assays designed by coworkers of the Charité are indicated by blue bars. b) PreAmp uniformity of the investigated candi-
date gene assays at 7 dilution steps from 25 ng/μl PBMCs' cDNA (1) to 1:1,024. The red bars indicate the means ± SD of the 8 
reactions for each gene assay.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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ferently compared to the remaining gene assays with
regard to the intra-assay CV (Figure 7). ABI inventoried
gene assays demonstrated a lower intra-assay CV (0.77 ±
0.45%) compared with the self-designed gene assays
(0.98 ± 0.41%; p = 0.0274) (Figure 6).
SSRT-PreAmp (sequence-specific reverse transcription 
followed by a multiplex PreAmp)
Employing SSRT-PreAmp, the investigated gene assays
yielded a mean improvement of 9.76 ± 2.45 Ct values
(range: 6.34 to 13.32). The mean Ct values obtained by
direct real-time RT-PCR were 33.07 ± 4.27 (range:
24.57–31.19), and the SSRT-PreAmp Ct values were 23.31
± 3.65 (range: 17.97–29.75; p < 0.0001 compared with
the Ct values derived from the direct real-time RT-PCR),
respectively. In one EMB, no traceable IFNg expression
was observed neither by direct nor by SSRT-PreAmp real-
time RT-PCR. Considering the threshold Ct for low
expression levels published by Canales et al [18], 12/27
(44%) of the target genes showed Ct values ≥ 35 in direct
real-time RT-PCR, whereas Ct values for HPRT-CCM dem-
onstrated <29 in each case of the 4 investigated EMBs. The
mean PreAmp uniformity of the investigated gene assays
related to HPRT-CCM was -3.29 ± 2.40 (range: -6.98 to
0.05; Figure 8), which was significantly (p < 0.0001) lower
compared with the T-PreAmp data. As in PBMCs, the gene
assays for CD3z, IFNg, T-bet and Perforin performed
below the PreAmp uniformity value of -1.5. The mean
inter-assay CV using the SSRT-PreAmp technique was
higher compared with T-PreAmp (5.38 ± 2.06; p = 0.01;
Figure 9). There was no association between the PreAmp
uniformity related to HPRT-CCM of target gene Ct values
in direct real-time RT-PCR < 35 (-3.1 ± 2.49) or ≥ 35 (-3.51
± 2.37). However, the SSRT-PreAmp yielded comparably
low intra-assay CVs as obtained by T-PreAmp (Figure 10).
The real-time RT-PCR results from each 10 DCMi- and
DCM-patients revealed differential expression with
respect to 30 out of the 92 (32%) investigated target
genes. These differential gene expressions were related to
both HPRT-CCM and CDKN1B. Significantly different
gene expressions related to HPRT-CCM are shown in
Table 1. The data of all investigated target genes related to
HPRT-CCM, including the non differentially expressed
genes, are listed in the Additional file 1. Gene expression
data related to CDKN1B are listed in the Additional file 2.
Significantly increased gene expression was determined
with respect to several T-cell related genes (CD3d, CD3z,
PreAmp uniformity in EMBs using T-PreAmp related to CDKN1B Figure 2
PreAmp uniformity in EMBs using T-PreAmp related to CDKN1B. Taqman® ABI inventoried gene assays are indi-
cated by red bars, self-designed gene assays designed by coworkers of the Charité are indicated by blue bars. Values are dis-
played as means ± SD. The turquoise (second to last) bar indicates the PreAmp uniformity mean ± SD from all gene assays 
excluding CD56, which is indicated by the last bar.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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TRBC, TRBV2, TRBV4, TRBV6, TRBV10, TRBV20, TRBV23,
TRBV24, TRBV29, NFATC3 (nuclear factor of activated T-
cells C3), interleukin 6 (IL6), tumor necrosis factor alpha
(TNFa), the chemokine CX3CL1 (fractalkine), cysteine-
rich angiogenic inducer 61 (CYR61), Th1 associated genes
(T-bet and eomesodermin), genes expressed by cytotoxic
T-lymphocytes (granzymes A and B, granulysin), β1-
integrins (av5b1), the selectin CD62E (E-selectin) and
growth-differentiation factor 15 (GDF15). The signifi-
cantly down-regulated genes in EMBs from DCMi-
patients were the chemokine CXCL14 (MIP-2g), adi-
ponectin (APN) and tissue factor (TF).
HPRT and CDKN1B are not regulated in DCM compared 
with donor hearts
The value of HPRT as housekeeping gene is well acknowl-
edged in various tissues. The close association between
HPRT-CCM and CDKN1B Ct values as well as the equally
significant differential expression of genes related to both
HPRT-CCM and CDKN1B in EMBs from DCM versus
DCMi patients infer a possible relevance of CDKN1B as a
housekeeping gene. To address this issue, we determined
the Ct values of HPRT (both HPRT-ABI and HPRT-CCM)
and CDKN1B by direct real-time RT-PCR in each 5
explanted donor and terminally failing DCM hearts, from
which enough tissue amounts were accessible to adjust
RNA to 50 ng/μl before cDNA synthesis. As stated above
for PBMCs, HPRT-ABI and HPRT-CCM demonstrated a
difference around 0.3 Ct values. There was no statistical
difference of Ct values of HPRT-ABI, HPRT-CCM and
CDKN1B in donor and DCM hearts (Figure 11).
Discussion
It is widely accepted that conventional histological diag-
nostics are not sufficient to elucidate the complex proc-
esses critically involved in the pathogenesis of DCMi, that
they clearly lack prognostic impact, and that they are not
sufficient to select DCM/DCMi patients who will likely
benefit from immunomodulatory treatment [9,19]. Gene
expression investigations are promising approaches for a
profound understanding of the pathogenesis of DCM/
DCMi, the prognostic impact of gene expression profiles
in the natural course of the disease as well as under immu-
nomodulatory treatment [4,11-13,16]. However, the
amount of tissue and RNA/cDNA available from EMBs is
limited, which restricts the number of analyzable target
genes per EMB. PreAmp procedures may enhance sensitiv-
ity of real-time RT-PCR especially for low abundance
PreAmp uniformity in EMBs using T-PreAmp related to HPRT-CCM Figure 3
PreAmp uniformity in EMBs using T-PreAmp related to HPRT-CCM. Taqman® ABI inventoried gene assays are indi-
cated by red bars, self-designed gene assays designed by coworkers of the Charité are indicated by blue bars. Values are dis-
played as means ± SD. The turquoise (second to last) bar indicates the PreAmp uniformity mean ± SD from all gene assays 
excluding CD56, which is indicated by the last bar.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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expressed genes, and can establish substantially higher
cDNA amounts, which can then expand the number of
the analyzable target genes from a limited cDNA. How-
ever, maintenance of gene expression profiles as well as a
broad applicability to many target genes with a feasible
additional effort is a further intriguing aspect of PreAmp
procedures.
The T-PreAmp technique enables a relatively simple work-
flow, which basically consists of setting up the primer/
gene assay pool and T-PreAmp of cDNA over 14 cycles in
a special master mix, maintaining robust PreAmp condi-
tions for several gene assays, which results in mostly stable
PreAmp uniformity values. Identical primers are used for
both the T-PreAmp reaction and the succeeding real-time
RT-PCR. This is substantially easier to accomplish com-
pared with the SSRT-PreAmp, which requires design of
specific primers for both the SSRT and the following
preamplification step [17].
According to the manufacturer's specifications, up to 100
gene assays can be preamplified simultaneously in each T-
PreAmp reaction, which is confirmed by our data on the
simultaneously preamplified 92 gene assays both in
PBMCs' and EMBs' cDNA. A further advantage of this
technique is that out of 60 μl cDNA obtained from the
herein applied RNA extraction and cDNA synthesis meth-
ods for EMBs, 8 different PreAmp reactions are feasible
from one single EMB, which would hypothetically enable
gene expression analysis of 784 different target genes
(minus one housekeeping gene such as HPRT, and
CDKN1B as the suggested reference gene for PreAmp uni-
formity). This is a substantially higher number of quanti-
fiable target genes compared with the direct conventional
real-time PCR, by which a maximum of 30 different target
genes would be applicable in duplicate real-time RT-PCR
analyses and 1 μl cDNA used in each reaction, and also
compared with the SSRT-PreAmp procedure, which
equally does not grant the possibility of expanding the
maximum possible real-time RT-PCR analyses out of a
limited amount of cDNA. This fact implies a further
advantage of a negligible sampling error for this high
putative number of real-time RT-PCR analyses carried out
from one EMB, as opposed to the situation in which gene
expression analyses would have to be split into different
groups of target genes on cDNA from several EMBs from
patients, given the limited RNA/cDNA amount available
from each EMB for direct real-time RT-PCR analyses.
Inter-assay variance of Ct improvement in EMBs using T-PreAmp Figure 4
Inter-assay variance of Ct improvement in EMBs using T-PreAmp. Ct improvement achieved by T-PreAmp from 4 
different EMBs (illustrated in 4 different colors) for each gene assay. The individual Ct values of CDKN1B and HPRT-CCM are 
not shown, since they were determined in all 38 EMBs.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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Noticeably, sampling error is a critical issue for the histo-
logical assessment of myocardial inflammation [20].
The T-PreAmp technique with 14 PreAmp cycles results in
a substantial increase of sensitivity of the real-time RT-
PCR by around 7 Ct values, with PreAmp uniformity val-
ues ranging between -1.5 to +1.5 both in PBMCs' and
EMBs' cDNA (except for the gene assays HPRT-ABI and
CD56). The low intra- and interassay CVs in EMBs cDNA
(<4%, including CD56) imply a high precision and
repeatability of the T-PreAmp procedure. Furthermore,
our data show that the PreAmp uniformity is maintained
over a broad range of Ct values in direct real-time PCR,
including low abundance Ct ranges (Ct ≥ 35 in direct real-
time RT-PCR) [18]. This applies to both Taqman® ABI
inventoried gene assays as well as to self-designed gene
assays adhering to ABI recommendations. As shown
herein, only the forward/reverse primers of self-designed
gene assays need to be included in the PreAmp Master Mix
reaction, and do not perform significantly different com-
pared with the ABI inventoried Taqman®  gene assays
regarding the PreAmp uniformity, of which both primers
and probes have to be pooled in the T-PreAmp reaction.
Moreover, we determined that the PreAmp uniformity is
also maintained with regard to gene assays using common
reverse primers and common probes but diverse forward
primers (TRBV primers) as well as to wobbled primer
designs (TRBV5, 6 and 7 forward primers). These numer-
ous advantages cannot be met by the SSRT-PreAmp proce-
dure. First, this technique is not feasible for ABI
inventoried Taqman® gene expression assays, since the
primer sequences of these assays are not accessible, and
therefore primer design for the SSRT-PreAmp steps is not
possible. Secondly, SSRT-PreAmp results on both PBMCs'
and EMBs' cDNA demonstrated highly diverging PreAmp
uniformity, with values below the suggested range of -1.5
to 1.5 with regard to CD3z, IFNg, T-bet and Perforin,
albeit the same gene assays performed within the sug-
gested PreAmp uniformity range of -1.5 to 1.5 using the
Taqman® PreAmp Master Mix. However, our data show
that both PreAmp procedures perform without signifi-
cantly different PreAmp uniformity values over a broad
range of Ct values in direct real-time PCR, including low
abundance Ct ranges (Ct ≥ 35 in direct real-time RT-PCR)
[18], which implies a potential application in preclinical
diagnostics especially for the T-PreAmp procedure due to
its numerous advantages (i.e. robust PreAmp uniformity
values for most gene assays, easier to use, expansion of
Inter-assay CV of Ct improvement in EMBs using T-PreAmp Figure 5
Inter-assay CV of Ct improvement in EMBs using T-PreAmp. Inter-assay CV of Ct improvement by T-PreAmp 
derived from 4 different EMBs. Taqman® ABI inventoried gene assays are indicated by red bars, self-designed gene assays 
designed by coworkers of the Charité are indicated by blue bars. The turquoise bar indicates the mean ± SD of the investigated 
gene assays.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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possible real-time PCR analyses out of limited RNA/
cDNA). One further important finding is the lack of trace-
able expression in both cDNA and T-PreAmp cDNA for
target genes and samples, in which no detectable Ct values
were obtained neither by direct real-time RT-PCR in cDNA
from both PBMCs and EMBs. This infers that both T- and
SSRT-PreAmp techniques yield reliable results and do not
produce erroneous values.
As a limitation of our study, the comparison of PreAmp
uniformity values of the investigated gene assays between
T-PreAmp and SSRT-PreAmp was based on HPRT-CCM
only, and not on CDKN1B, since the latter Taqman® ABI
inventoried gene assay is not applicable to SSRT-PreAmp.
However, T-PreAmp data on HPRT-CCM indicate that this
gene assay can be equally used as referral gene assay for
the calculation of the PreAmp uniformity. This infers that
not the design characteristics of these gene assays (i.e. PCR
efficiency), but rather the PreAmp procedure per se is the
decisively important issue leading to the observed discrep-
ancies of PreAmp uniformity values. It is possible that
interactions of the primers of the different gene assays
during the SSRT-PreAmp procedure may lead to the
observed bias in PreAmp uniformity. This is in line with
our observations on the more pronounced distortion of
the PreAmp uniformity values when adding more gene
assays into the SSRT-PreAmp reactions (data not shown).
Due to the higher complexity of the SSRT-PreAmp proce-
dure and the expected higher chance of primer interac-
tions during PreAmp, we did not investigate the PreAmp
characteristics of the gene assays using common reverse
primers/probes and diverse forward primers, nor wobbled
primer designs (TRBV primers), with the SSRT-PreAmp
procedure. Nested PCR techniques have a higher specifi-
city compared with non-nested PCR [21], and real-time
RT-PCR is known to have a higher specificity compared
with nested PCR [22]. Thus, the advantage of the SSRT-
PreAmp approach might be the higher specificity due to
the nested primer design. Since the recipe of the T-PreAmp
Master Mix® is not accessible, we cannot speculate on the
decisively important factors responsible for the observed
disparity of the PreAmp uniformity of the T-PreAmp and
the SSRT-PreAmp, so far. Possibly, the SSRT before the
multiplex nested PreAmp may lead to the high diversity of
PreAmp uniformity of the SSRT-PreAmp procedure, and
this distortion is more pronounced regarding the gene
assays CD3z, IFNg, T-bet and Perforin. Nonetheless, the
equally low intra-assay CVs using both SSRT-PreAmp and
T-PreAmp indicate that the SSRT-PreAmp is an equally
reproducible approach, albeit potentially leading to more
Intra-assay variance in EMBs using T-PreAmp Figure 6
Intra-assay variance in EMBs using T-PreAmp. Ct values resulting from 5 different T-PreAmp reactions from cDNA aliq-
uots derived from one EMB illustrated in 5 different colors. Taqman® ABI inventoried gene assays are indicated by red bars, 
self-designed gene assays designed by coworkers of the Charité are indicated by blue bars.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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pronounced skewing of the calculation of relative gene
expressions. However, the higher inter-assay CVs
obtained by SSRT-PreAmp, although still <10%, indicate
that the T-PreAmp technique leads to a higher precision
for the direct comparison in the relative quantification of
gene expression analyses between samples.
Our data show that the PreAmp uniformity of the T-
PreAmp technique depends on the respective gene assay
PreAmp uniformity in EMBs using SSRT-PreAmp related to  HPRT-CCM Figure 8
PreAmp uniformity in EMBs using SSRT-PreAmp 
related to HPRT-CCM. Values are displayed as means ± 
SD. The turquoise bar indicates the PreAmp uniformity mean 
± SD of all investigated self-designed gene assays.
Intra-assay CVs in EMBs using T-PreAmp Figure 7
Intra-assay CVs in EMBs using T-PreAmp. Intra-assay CVs resulting from 5 different T-PreAmp reactions from cDNA 
aliquots derived from one EMB illustrated. Taqman® ABI inventoried gene assays are indicated by red bars, self-designed gene 
assays designed by coworkers of the Charité are indicated by blue bars. The turquoise bar indicates the mean ± SD from all 
investigated gene assays.
Inter-assay variance and CV of Ct improvement in EMBs  using SSRT-PreAmp Figure 9
Inter-assay variance and CV of Ct improvement in 
EMBs using SSRT-PreAmp. a) CV of Ct improvement by 
T-PreAmp and b) inter-assay CVs for the investigated gene 
assays derived from 4 different EMBs (illustrated in 4 differ-
ent colors) by SSRT-PreAmp. The turquoise bar indicates the 
mean ± SD of the investigated gene assays.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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both in PBMCs' and EMBs' cDNA, and implies that gene
assays should be tested for PreAmp uniformity before set-
ting up serial T-PreAmp investigations. The two gene
assays, which did not perform comparably to the sug-
gested T-PreAmp uniformity reference gene assay
CDKN1B, were HPRT-ABI and CD56 (both Taqman® ABI
inventoried gene assays). As a consequence, calculation of
expression profiles of all target genes would be substan-
tially altered, if HPRT-ABI would be used as a housekeep-
ing gene assay in T-PreAmp real-time RT-PCR analyses,
which emphasizes the value of PreAmp uniformity testing
referring especially to a possible housekeeping gene can-
didate. In line with our observations, Denning et al. pre-
viously identified that the GAPDH Taqman®  ABI
inventoried gene assay does not maintain the suggested
PreAmp uniformity values. Therefore, these authors also
normalized gene expression to CDKN1B, as well [23].
Nonetheless, as shown for CD56, the low inter- and intra-
assay variations of the PreAmp technique (CVs <4%) war-
rants a high reproducibility of the PreAmp real-time RT-
PCR results, even for the gene assays identified to show
substantially altered PreAmp uniformity values out of the
suggested range between -1.5 and +1.5. However, in the
context of the relatively robust PreAmp uniformity per-
formance of the T-PreAmp technique (especially com-
pared to the SSRT-PreAmp procedure), one should also
consider the PCR efficiency of the respective gene assays,
since the "true" range of PreAmp uniformity hypotheti-
cally rises with decreasing PCR efficiency. Furthermore,
the impact of contaminating DNA can be theoretically sig-
nificant in such low-level expression levels of the target
transcripts. The intron spanning primer design avoiding
co-amplification of genomic DNA of both the self-
designed and of the Taqman® ABI inventoried gene assays,
however, and the missing cross reactivity with genomic
DNA tested in DNA from PBMCs largely excludes an
impact of this theoretically problematic issue in our inves-
tigations. Our investigations on possible causes for dis-
proportionate T-PreAmp uniformities, although not
elucidating the concrete reason, reveal that the T-PreAmp
performance does not depend on the amplicon length
and on the PCR efficiency of the respective gene assays.
Denning et al. deduced from their investigations on
GAPDH (122 bp) and 12 further gene assays with shorter
amplicon lengths, that the amplicon length might be cru-
cially important for T-PreAmp uniformity [23]. However,
our data cannot confirm this hypothesis, especially since
the TRBV19 and TRBV29 gene assays yielding amplicons
around 260 bp and 320 bp (depending on the respective
diversity and joining regions) resulted in PreAmp uni-
formities in the range between -1.5 and +1.5, performing
comparably to further self-designed gene assays (i.e.
HPRT-CCM: 101 bp; CD3z: 108 bp; TRBC: 151 bp), and
Taqman® ABI inventoried gene assays (i.e. CD3d: 92 bp;
NFATC3: 74 bp; av5b1: 75 bp). There was no evidence for
an impact of the PCR efficiency of these gene assays on the
PreAmp uniformity. In contrast, the Taqman® ABI inven-
toried gene assays HPRT-ABI (100 bp) and CD56 (61 bp)
showed substantially lower improvement of Ct values
under the same conditions. Noticeably, this distortion of
PreAmp uniformity was stable at the serial cDNA dilu-
tions regarding HPRT-ABI, whereas the CD56 gene assay
showed an increasing PreAmp uniformity with decreasing
PCR efficiency at serial cDNA dilutions. We therefore con-
clude that distortion of T-PreAmp uniformity is gene assay
specific and not a general problem of the T-PreAmp tech-
nique. These findings add clarity, however, are trouble-
some at the same time, since the concrete reason for
disproportionate T-PreAmp performance of certain gene
assays still remains unclear. Nonetheless, these data again
highlight the importance of PreAmp uniformity pretests
before setting up serial investigations using the T-PreAmp
technique. To gather, compare and discuss the experiences
especially on the obvious distortion of T-PreAmp uni-
formity with regard to particular gene expression assays,
we propose the constitution of a central open access
forum. In light of the possible impact of primer interac-
tions during the T-PreAmp reaction, of RNA quality and
DNA contamination, this forum should not only refer to
the T-PreAmp performance of single gene assays, but also
incorporate the precise gene assay mix in the respective T-
PreAmp reaction, the applied RNA extraction technique,
RNA quality and DNA contamination issues. Hopefully,
the decisively important design characteristics of gene
Intra-assay variance and CVs in EMBs using SSRT-PreAmp Figure 10
Intra-assay variance and CVs in EMBs using SSRT-
PreAmp. a) Ct values resulting from 5 different T-PreAmp 
reactions and b) the resulting intra-assay CVs from cDNA 
aliquots derived from one EMB by SSRT-PreAmp. The tur-
quoise bar in panel b indicates the mean ± SD from all inves-
tigated gene assays.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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assays leading to a substantial deviation of the T-PreAmp
uniformity can be identified, eventually. These insights
might lead to additional rules of gene assay design, by
which the T-PreAmp uniformity can be predicted.
Several gene expression analyses have been reported com-
paring heart failure to non-failing hearts, or different car-
diomyopathy entities. In this preliminary analysis, we
compared EMBs from 10 DCM patients with 10 patients
with immunohistologically confirmed DCMi. Both
HPRT-ABI, HPRT-CCM and CDKN1B in donor and DCM hearts Figure 11
HPRT-ABI, HPRT-CCM and CDKN1B in donor and DCM hearts. Ct values of HPRT-ABI, HPRT-CCM and CDKN1B 
in each 5 donor hearts and 5 explanted DCM hearts (RNA subjected to cDNA synthesis adjusted to 50 ng/μl).
Table 1: Differential gene expression results in EMBs from DCM and DCMi patients related to HPRT-CCM and CDKN1B using T-
PreAmp
Gene DCM DCMi p value
CD3d 0.014163 ± 0.008761 0.045395 ± 0.015252 <0.0001
CD3z 0.043139 ± 0.010119 0.060631 ± 0.007718 0.0023
TRBC 0.015027 ± 0.010150 0.027622 ± 0.010532 0.0098
TRBV2 0.001487 ± 0.001300 0.004503 ± 0.002881 0.0053
TRBV4 0.001501 ± 0.001432 0.005441 ± 0.003850 0.0047
TRBV6 0.002926 ± 0.002154 0.005478 ± 0.002562 0.0307
TRBV10 0.000186 ± 0.000127 0.000905 ± 0.000967 0.0245
TRBV20 0.003935 ± 0.003140 0.019818 ± 0.018318 0.0105
TRBV23 0.000408 ± 0.000269 0.006402 ± 0.008324 0.0270
TRBV24 0.000282 ± 0.000265 0.004754 ± 0.006232 0.0075
TRBV29 0.001302 ± 0.001168 0.002815 ± 0.00138 0.0192
IL6 0.002020 ± 0.001246 0.004133 ± 0.002452 0.0094
TNFa 0.028511 ± 0.014230 0.052024 ± 0.017001 0.0049
CXCL14 0.151853 ± 0.145437 0.054158 ± 0.052000 0.0299
CX3CL1 0.96874 ± 0.431717 1.39651 ± 0.790158 0.0245
APN 0.390377 ± 0.555952 0.035850 ± 0.058782 0.0092
NFATC3 1.29493 ± 0.479396 2.56855 ± 0.776956 0.0052
CYR61 0.85785 ± 0.47640 2.94840 ± 2.33843 <.0001
TF 3.59608 ± 1.01046 2.14158 ± 0.53169 0.0109
T-bet 0.014431 ± 0.005826 0.022267 ± 0.008127 0.0355
Granzyme A 0.014704 ± 0.006914 0.035028 ± 0.011726 0.0004
Granzyme B 0.062487 ± 0.022406 0.105532 ± 0.026082 0.0027
Granulysin 0.206285 ± 0.186560 0.532339 ± 0.327002 0.0183
Eomesodermin 0.014428 ± 0.007246 0.036024 ± 0.007900 0.0011
av5b1 1.04571 ± 0.283760 1.71316 ± 0.844310 0.0033
GDF15 0.020984 ± 0.013187 0.041715 ± 0.028283 0.0127
CD62E 0.002714 ± 0.001093 0.012877 ± 0.008890 0.0119
Significantly different gene expression (E; normalized to the housekeeping genes HPRT-CCM or CDKN1B) T-PreAmp real-time RT-PCR results in 
EMBs from DCM patients compared with EMBs from patients with immunohistologically confirmed DCMi (>7 CD3+ infiltrates/mm2). The values are 
given as means ± SD, followed by the respective p values in significantly different comparisons.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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patient groups had comparably depressed LVEF, which
alleviates a possible bias of secondary general heart-failure
associated mechanisms. Our preliminary data from these
T-PreAmp real-time RT-PCR analyses revealed differential
gene expression with respect to 27/90 (30%) of the inves-
tigated target genes. In brief, these investigations con-
firmed that the immunohistologically diagnosed DCMi is
accompanied by a significantly increased expression of T-
cell related genes (CD3d, CD3z, TRBC and NFATC3). Up-
regulation of distinct TRBV families (TRBV2, 4, 6, 10, 20,
23, 24 and 29) in EMBs from DCMi patients indicates a
selective recruitment and/or expansion, and therefore
restriction of TRBV usage of the T-cell infiltrates in DCMi
[24]. The increased expression of IL6, TNFa and CX3CL1
infer that T-cell infiltration in DCMi is paralleled by differ-
ential increment of these cytokines, whereas a further
chemokine, CXCL14, was confirmed to be downregulated
in DCMi patients as recently reported for DCMi patients
with slightly impaired LVEF by microarray analyses [15].
Furthermore, in line with these microarray findings, our
investigations confirmed a down-regulation of APN,
while its receptors APN-R1 and APN-R2 were not differen-
tially expressed, and an up-regulation of CYR61 [15]. The
results on markers of T-cell activation reveal a yet not rec-
ognized potential role of Granzymes A and B, Granulysin,
as well as T-bet and eomesodermin as markers for cyto-
toxic and Th1-polarized T-cells, respectively, in DCMi. In
contrast, markers for Th2-polarized T-cells, anergic and
regulatory T-cells (IL4, IL5, IL10, TGFb, GATA3, GRAIL,
FoxP3) were not increased in EMBs from patients with
immunohistologically confirmed DCMi, which might
indicate a missing counter-balance of the T-cellular
response in DCMi. The lack of differential expression of
Toll-like receptors (TLRs) and signaling factors involved
in TLR downstream pathways do not favor the hypothesis
of a paramount role of TLRs in DCMi, so far. Our analyses
furthermore confirmed downregulation of intramyocar-
dial TF expression in DCMi versus DCM patients [25].
Whilst altered expression of several components of the
extracellular matrix is well known in DCM and further
non-DCM cardiomyopathies [14,26], no direct link to
inflammation or cardiotropic viral infection has been
described, so far. Our preliminary data do not show any
differential expression of collagen types I, III and IV,
MMPs 2, 8, 9, TIMPs 1, 4 and uPA in EMBs from DCMi
versus DCM patients. Increased expression of β1-integrins
and further adhesion molecules such as CD62E have been
confirmed by immunohistological analyses [1], which is
in line with our data on av5b1 and CD62E. GDF15 is a
newly recognized marker of heart failure, and our data
implicate an additional role of DCMi for increased
GDF15 expression [27]. In summary, these preliminary
analyses confirm that the T-PreAmp procedure, in addi-
tion to its technical applicability to EMBs, thereby
expanding the number of analyzable target genes in EMBs
investigations, is capable of revealing significantly differ-
ent gene expression profiles in DCMi versus DCM
patients. Albeit numerous reports have confirmed close
associations between RNA and protein gene expression, a
discrepancy between these two levels of gene expression
was elucidated in some investigations, i.e. due to post-
translational modification [28,29]. We show here a signif-
icant association between expression of T-cellular markers
(CD3d, CD3z, TRBC, NFATC3) and DCMi as determined
by immunohistologically quantified CD3+  infiltrates.
Although it would be beyond the scope of this methodol-
ogy paper, significantly different gene expression analyses
as determined by PreAmp real-time PCR should be ideally
confirmed by protein expression analyses in future inves-
tigations.
Further investigations on larger patient cohorts are war-
ranted to explore associations with the various cardio-
tropic viruses [2,30], the impact of LVEF, the acuity of the
disease (i.e. patients presenting with acute myocarditis
versus DCM), the prognostic role of gene expression for
the diverse natural course of the disease (improvement
versus further deterioration under heart failure medica-
tion) [3], as well as the changes of gene expression in
DCMi patients under immunomodulatory treatment
modalities (i.e. immunosuppression, immunoadsorp-
tion, antiviral treatment; [4,11-13,16]). The application of
the T-PreAmp procedure might be especially useful in
light of the new EMB guidelines [31]. Moreover, these
promising results of T-PreAmp real-time RT-PCR in EMBs
might be stimulating for researchers analyzing biopsies or
comparably small sized tissue samples from other organs,
and for PreAmp real-time RT-PCR analyses from limited
cell amounts such as those obtained by laser capture
microdissection [23,32].
Finally, we here provide first evidence that CDKN1B, in
addition to its function as the suggested reference gene for
the PreAmp uniformity, can be used as a relevant house-
keeping gene for the relative quantification of gene expres-
sion in real-time RT-PCR in myocardial tissues, equivalent
to HPRT. Whereas the tumor suppressor gene function of
CDKN1B is well understood in other tissues and patho-
logic conditions [33,34], the physiological role and
expression pattern of CDKN1B in myocardial tissues has
not been investigated, yet. Congruent with our observa-
tions, Denning et al. have previously confirmed that
CDKN1B can also serve as housekeeping gene in thyroid
tissues [23].
Conclusion
In comparison to the SSRT-PreAmp, T-PreAmp enables a
relatively simple workflow, and results in a robust
PreAmp of multiple target genes (at least 92 gene assays as
tested here) by a mean Ct improvement around 7 cycles,BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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and in a lower inter-assay variance in RNA derived from
EMBs. Preliminary analyses comparing EMBs from DCM
and DCMi patients, revealing differential regulation
regarding 30% of the investigated genes, confirm that T-
PreAmp is a suitable tool to perform gene expression anal-
yses in EMBs, expanding gene expression investigations
with the limited RNA/cDNA amounts derived from EMBs.
CDKN1B, in addition to its function as a reference gene
for the calculation of PreAmp uniformity, might serve as a
suitable housekeeping gene for real-time RT-PCR analyses
of myocardial tissues.
Methods
Patients and sample preparation from peripheral blood 
monocytes (PBMCs) and myocardial tissues
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from peripheral blood obtained from 5 adult
healthy donors (each 3 ml) in Vacutainer® EDTA tubes
(BD Biosciences, Heidelberg, Germany) within 10 min-
utes after blood drawing using the LSM 1077 Lymphocyte
Separation Medium (PAA, Pasching, Germany) density
gradient. PBMCs were lysed in RLT®  buffer (Qiagen,
Hilden, Germany), and total RNA was gained using the
Qiagen spin column system according to the manufac-
turer's instructions. RNA from each individual was
adjusted to 25 ng/μl. After reverse transcription (RT),
cDNAs were diluted at 1:50, which resulted in comparable
direct real-time RT-PCR Ct values as cDNA from EMBs.
PBMCs' cDNA from these 5 subjects were pooled to min-
imize missing expressions especially for cytokines. RNA
concentrations of both PBMCs and myocardial tissues
were quantified using the Nanodrop® ND-1000 spectro-
photometer (Agilent Technologies, Böblingen, Germany).
EMBs from n = 36 DCM patients (8/22% females; age:
38.2 ± 12.7 years; LVEF: 37.7 ± 17.4%) were used for the
determination of the mean improvement of Ct values and
of the PreAmp uniformity related to CDKN1B and HPRT-
CCM as well as the inter-assay variance of PreAmp using
the T-PreAmp technique. Due to limited amounts of
cDNA, groups of each 9 or 10 target gene assays in addi-
tion to CDKN1B and HPRT-CCM were determined in 4
EMBs per gene assay group. For the SSRT-PreAmp investi-
gations, EMBs from 4 further DCM patients (all males,
age: 41.2 ± 5.6 years, LVEF: 35.1 ± 9.1%) were used. Intra-
assay variance was determined in 5 aliquots of cDNA from
each one EMB for both PreAmp techniques, in which
direct real-time RT-PCR showed expression of all investi-
gated gene assays.
To determine preliminary data on differential gene expres-
sion by real-time PCR using the T-PreAmp technique, we
selected EMBs from 20 patients presenting with DCM
(LVEF: 25.1 ± 7.6%; age: 49.6 ± 13.8 years, males/females:
16/4). In ten of these patients, DCMi was confirmed by
routine EMBs analyses (CD3+ infiltrates: 14.8 ± 5.1/mm2;
Parvovirus B19 in n = 6, human herpes virus type 6 in 3,
and one case with co-infection with both viruses; [1,2]),
whereas the EMBs of the remaining 10 patients did not
show any immunohistological characteristics of increased
T-cell infiltration (CD3+: 3.2 ± 2.3/mm2), and no cardio-
tropic viral infection.
Total RNA was isolated from EMBs (3–6 mg tissue) using
TRIZOL® (Invitrogen, Karlsruhe, Germany) and was puri-
fied using the ChargeSwitch® Total RNA Cell Kit (Invitro-
gen, Karlsruhe, Germany). Mean RNA concentrations of
the EMBs were 26.7 ± 13.2 ng/μl.
To ascertain whether CDKN1B and HPRT are regulated in
myocardial tissues, we determined the Ct values for both
genes in 5 snap frozen myocardial samples from donor
hearts and from 5 explanted DCM hearts (all males; age:
45.6 ± 6.7 years; LVEF ≤ 25%) adjusted at 50 ng/μl RNA
before retrotranscription.
Reverse transcription to cDNA from RNA extracted from
both PBMCs and myocardial tissues was carried out using
the high capacity archive kit (Applied Biosystems/ABI,
Darmstadt, Germany) according to the manufacturer's
instructions. 60 μl of PBMCs' RNA and 30 μl of RNA from
EMBs were transcribed to a final volume of 120 μl and 60
μl, respectively.
These investigations were approved by the local ethics
committee at the Charité – Universitätsmedizin Berlin in
the framework of the Sonderforschungsbereich TR19 in
compliance with the Helsinki Declaration. Every patient
gave informed consent.
Design of primers and probes and Taqman® ABI 
inventoried gene assays
For the gene assay design of the T-cell receptor Vβ variable
region (TRBV) and TRB constant region (TRBC) primers
and probes, we used the gene sequences published at the
Immunogenetics Database [35]. Primers and probes were
designed using the Primer Express Software (version 2.0;
ABI, Darmstadt, Germany) according to ABI recommen-
dations. Sequence homologies between the various func-
tional TRBVs were excluded by multiple alignment using
ClustalX Software (version 1.83; University of Strasbourg,
France). We chose TRBV specific forward primers and one
common reverse TRB primer on the constant TRB (TRBC)
region and a probe on the TRBC region (encompassing
both human TRBC1 and TRBC2). A further gene assay was
designed on the constant region of the TRBC (encompass-
ing both human TRBC1 and TRBC2). For TRBV5, 6, and
7, wobbled (WBL) primers were designed to encompass
few base differences. TRBV and TRBC minor groove
binder (MGB) probes were synthesized by Applied Biosys-BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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tems (ABI; Darmstadt, Germany). Primers and probes for
HPRT-CCM, IL-10, IFN-g, TGF-b, FoxP3, T-bet, GATA3,
granzyme A and B, granulysin and perforin were designed
using the Oligo 4.1 software (Molecular Biology Insights,
Cascade USA) and published genomic sequences
(National Center for Biotechnology Information/NCBI)
according to ABI recommendations. The sequences of the
primers are listed in Table 2, and of the fluorescence
hybridization probes in Table 3, respectively. All probes
used were FAM dye (carboxyfluorescein) labeled. The
primers and probe for tissue factor (TF) has been pub-
lished elsewhere [25]. All primers and probes (except for
TRBV and TRBC MGB-probes) were synthesized by Meta-
bion (Martinsried, Germany). The ABI inventoried Taq-
Man® gene expression assays are listed in Table 4. All self-
designed gene assays followed an intron spanning design
according to ABI recommendations, and thus, as well as
the applied Taqman® ABI inventoried gene assays, did not
show any cross reactivity with genomic DNA extracted
from PBMCs.
T-PreAmp procedure
The pooled TaqMan®  assays (including fluorescent
probes) as well as the self-designed forward/reverse prim-
Table 2: Sequences of primers and probes of self-designed real-time RT-PCR gene assays
Gene name 5' sense 3' primer sequence 5' antisense 3' primer sequence
TRBC TCCGCTGTCAAGTCCAGTTCTA GACAGGACCCCTTGCTGGTA
TRBV common antisense primer CTGCTTCTGATGGCTCAAACA
TRBV2 ACTCTGAAGATCCGGTCCACAA
TRBV3 ATCAATTCCCTGGAGCTTGGT
TRBV4 CCTGAATGCCCCAACAGC
TRBV5 GCTCTGAGCTGAATGTGAACGC
TRBV5WBL GCTCTGAGATGAATGTGAGTGC
TRBV6 CACTGACAAAGGAGAAGTCCC
TRBV6WBL6-2 AACTGCCAAAGGAGAGGTCCC
TRBV6WBL6-4 CACTGGCAAAGGAGAAGTCCC
TRBV7 CTCTCAGGTGTGATCCAATTTCG
TRBV7WBL7-2;7-3 AGCTCAGGTGTGATCCAATTTCA
TRBV7WBL7-9 CTTTCAGGTGTGATCCAATTTCT
TRBV9 CACAACAGTTCCCTGACTTGCA
TRBV10 CATGGGCTGAGGCTGATC
TRBV11 CTGCAGAGAGGCTCAAAGGAGTAG
TRBV12 AGAACCCAGGGACTCAGCTGT
TRBV13 GAACTGAACATGAGCTCCTTGGA
TRBV14 CTGAAAGGACTGGAGGGACGTAT
TRBV15 CAGGAGGCCGAACACTTCTTT
TRBV16 GCCTCCCAAATTCACCCTGTA
TRBV18 CCAGCATCCTGAGGATCCA
TRBV19 ACTGTGACATCGGCCCAAA
TRBV20 AACCATGCAAGCCTGACCTT
TRBV23 CCCTGCAGCCTGGCAAT
TRBV24 GCTAAATTCTCCCTGTCCCTAGAGT
TRBV25 TTCCCCTGACCCTGGAGTCT
TRBV27 GGCTTAAGGCAGATCTACTATTCAATG
TRBV28 GCCAGCACCAACCAGACAT
TRBV29 AGCCGCCCAAACCTAACATT
TRBV30 CGGCAGTTCATCCTGAGTTCT
HPRT-CCM AGTCTGGCTTATATCCAACACTTCG GACTTTGCTTTCCTTGGTCAGG
IL10 CAAGTTGTCCAGCTGCTTCAT TTGGCGAAAGCAGCTCCTC
IFNγ CAGGTCATTCAGATGTAGCGGATAA AGGAGACAATTTGGCTCTGCATT
TGFβ CCCTGCCCCTACATTGGAG CCGGTTATGCTGGTTGTACA
FoxP3 TGGCAAACGGAGTCTGCAA TCTCATCCAAGAGGTGATCTGCTT
T-bet CAACACAGGAGGCGCACTGG CCCCCTTGTTGTTTGTGAGCT
GATA3 CCTCATTAAGCCCAAGCGAAG TTGGCATTTCCTCCAGAGT
GRAIL GAAGCAGAGGCAATTAAAGGCAG CATCAGGGCCAATTTCCTTGT
Granzyme A CCCTGTGATTGGAATGAATATGGT ACACCCTCGCACAACAAAGG
Granzyme B GCGAATCTGACTTACGCCATTATT CAAGAGGGCCTCCAGAGTCC
Granulysin AAAACTGAAGAAGATGGTGGATAAGC ATCGTGACCTCCCCGTCCTA
Perforin GGACCAGTACAGCTTCAGCACTG AGTCAGGGTGCAGCGGG
Sequences of primers of self-designed real-time RT-PCR gene assays. For the different TRBV forward primers, one common reverse primer and one 
common MGB hybridization probe was designed. Wobbled (WBL) forward primers were used for TRBV5, 6 and 7.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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ers were diluted with 1 × Tris-EDTA (TE) buffer, so that
each assay was at a final concentration of 0.2 fold in the
PreAmp primer/assay pool according to the manufactur-
ers' instructions. Since initial experiments comparing the
volume of PreAmp reaction suggested by ABI (total
PreAmp reaction volume: 50 μl) and the half of the vol-
ume of PreAmp reaction recommended by the manufac-
turer (25 μl PreAmp reaction volume) showed identical
PreAmp results, we used the latter approach further on
due to reasons of cost-effectiveness. The herein used
PreAmp reaction conditions involved the amplification of
6.25 μl cDNA in a 25 μl reaction consisting of 12.5 μl Taq-
Man® PreAmp Master Mix and 6.25 μl pooled primer/
assay mix (0.2×, each assay). T-PreAmp of this primer/
gene assay pool was carried for 14 cycles on a PTC-100
Programmable Thermal Controller (MJ Research, Inc.,
Watertown, Mass., USA) with the following program:
denaturation at 95°C for 10 min and 14 cycles of ampli-
fication (15 sec at 95°C, 4 min at 60°C). The preampli-
fied products were then diluted with Tris-EDTA-buffer at a
ratio 1:20 (resulting volume 500 μl) and were used as
templates for the real-time RT-PCR analysis (Figure 12).
SSRT-PreAmp procedure
SSRT-PreAmp was applied to 8 self-designed gene assays
(HPRT-CCM and 7 T-cell related gene assays: CD3z, IFNg,
FoxP3, T-bet, GATA3, Granulysin and Perforin). Isolated
RNA was reverse transcribed using a sequence-specific 3'
primer instead of oligo dT primers (Table 5). This
Table 4: ABI inventoried Taqman® gene expression assays
Gene name ABI ID number
CDKN1B Hs00153277_m1
HPRT-ABI Hs99999909_m1
CD3D Hs00174158_m1
IL-1β Hs00174097_m1
IL-2 Hs00174114_m1
IL-4 Hs00174122_m1
IL-5 Hs00174200_m1
IL-6 Hs00174131_m1
IL-17 Hs00174383_m1
IL-27 Hs00377366_m1
IFN-β Hs01077958_s1
TNFα Hs00174128_m1
CXCL14 Hs00171135_m1
CX3CL1 Hs00171086_m1
APN Hs00605917_m1
APN-R1 Hs00360422_m1
APN-R2 Hs00226105_m1
NFATC3 Hs00190046_m1
CYR61 Hs00155479_m1
Ku70 Hs01922652_g1
Ku80 Hs00221707_m1
MAN1A2 Hs00198611_m1
Eomesodermin Hs00172872_m1
RHAMM Hs00234864_m1
RhoGTPAse1 Hs00205507_m1
RhoGTPAse2 Hs00183269_m1
TLR3 Hs00152933_m1
TLR4 Hs00370853_m1
TLR7 Hs00152971_m1
TLR8 Hs00152972_m1
TLR9 Hs00370913_s1
MYD88 Hs00182082_m1
TRAF3 Hs00377462_m1
TRAF6 Hs00270336_m1
IRF3 Hs00155574_m1
IRF7 Hs00242190_g1
MAPK8 Hs00177083_m1
MAPK14 Hs00176247_m1
STAT1 Hs00234829_m1
SOCS-3 Hs00269575_s1
AP-1 Hs00277190_s1
HSP70 Hs00382884_m1
Laminin Hs00165042_m1
Collagen I Hs00164004_m1
Collagen III Hs00164103_m1
Collagen IV Hs00266237_m1
MMP2 Hs00234422_m1
MMP8 Hs00233972_m1
MMP9 Hs00234579_m1
TIMP1 Hs00171558_m1
TIMP4 Hs00162784_m1
uPA Hs00170182_m1
GDF15 Hs00171132_m1
CD62E Hs00174057_m1
CD56 Hs00169851_m1
TIMP4 Hs00162784_m1
ABI inventoried Taqman® gene expression assays and the respective 
ABI ID numbers.
Table 3: Sequences of fluorescence hybridization probes
Gene name Sequence
TRBC ACGAGTGGACCCAGGATAGGGCCAA
TRBV common probe CACCCGAGGTCGCT
HPRT-CCM TTTCACCAGCAAGCTTGCGACCTTGA
IL10 TTACAGGACCAGAGGGACAAGACATGA
CTGTG
IFNγ TTTCTGTCACTCTCCTCTTTCCAATTCT
TCAAA
TGFβ CACGCAGTACAGCAAGGTCCTGGCC
FoxP3 AGCCGGGAGAGTTTCTCAAGCACTGC
T-bet CACCTGTTGTGGTCCAAGTTTAATCAG
CACC
GATA3 TCCTGTGCGAACTGTCAGACCACCAC
GRAIL GGAAGGCTTCAACTACGCACACTGAAA
CAAG
Granzyme A CTTCCAGAATCTCCAATTGCGCGAGTC
TCTTC
Granzyme B CCCACGCACAACTCAATGGTACTGTCG
Granulysin ACCCAGAGAAGTGTTTCCAATGCTGCG
AC
Perforin TGCCGCTTCTACAGTTTCCATGTGGTA
CAC
Sequences of fluorescence hybridization probes of self-designed real-
time RT-PCR gene assays. For the different TRBV forward primers, 
one common MGB hybridization probe was used.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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sequence specific reverse transcription was carried out
simultaneously for every gene of interest (n = 8) in the
same reaction. Afterwards, a first multiplex PCR consisting
of 10 cycles was run, in which all genes were amplified
simultaneously adding the amplification primers. Next, a
real-time RT-PCR applying nested amplification primers
and fluorogenic probes was performed amplifying each
gene separately. cDNA was used in a first round of multi-
plex PCR amplification. An aliquot of 5 μl of the RT reac-
tion was amplified in a final volume of 20 μl of PCR mix
containing 50 mmol/l KCl, 10 mmol/l Tris-HCl at pH 8.3,
2 mmol/l MgCl2, 0.2 mmol/l dNTPs, 3 units of AmpliTaq
Gold DNA Polymerase (ABI; Darmstadt, Germany), and
0.015  μmol/l of specific amplification primers for all
investigated self-designed genes (Table 2). The 3' primers
applied were the same as for cDNA synthesis. The cycle
program consisted of one step of denaturation at 95°C for
10 min and 10 cycles of amplification (45 sec at 95°C, 60
sec at 62°C, 90 sec at 72°C). The SSRT-PreAmp steps are
illustrated in Figure 13.
Real-time RT-PCR, PreAmp uniformity, intra- and inter-
assay variance
The real-time RT-PCR reactions were performed in a final
volume of 12.5 μl, containing 2 μl cDNA, 6.25 μl Master
Mix (TaqMan™ Universal PCR Master Mix, No AmpErase®
UNG, ABI, Darmstadt, Germany), 0.21 μl probe (final
concentration 0.05 μM) and 1.25 μl forward and reverse
primers (final concentration 0.9 μM). The PCR reactions
for TaqMan® gene expression assays contained 2 μl cDNA,
6.25 μl Master Mix and 0.625 μl TaqMan® gene expression
assay. Reactions were made up to a final volume of 12.5
μl with sterile water. All experiments were performed in
duplicate on an ABI 7900 HT Fast real-time PCR System
(Applied Biosystems, Darmstadt, Germany). The real-
time RT-PCR protocol was as following: Denaturation by
a hot start at 95°C for 10 min, followed by 40 cycles of a
two-step program (denaturation at 95°C for 15 sec and
annealing/extension at 60°C for 1 min). Gene expression
(E) was normalized to HPRT-CCM or CDKN1B applying
the formula: 2-ΔCt.
PreAmp uniformity related to CDKN1B (reference gene
suggested by ABI for the determination of PreAmp uni-
formity) and HPRT-CCM was calculated according to the
following formula:
ΔCt PreAmp = average Ct target × [PreAmp] - average Ct 
CDKN1B or HPRT-CCM [PreAmp].
Similarly, the average Ct from non-PreAmp cDNA tem-
plate were normalized to the average Ct of the uniformity
reference gene according to the following formula:
ΔCt cDNA = average Ct target × [cDNA] - average Ct 
CDKN1B or HPRT-CCM [cDNA].
The ΔΔCt was determined by the difference of the two
ΔCts:
ΔΔCt = ΔCt [PreAmp] - ΔCt [cDNA].
T-PreAmp procedure Figure 12
T-PreAmp procedure. Principle of the T-PreAmp tech-
nique: After standard reverse transcription, cDNA was 
preamplified (14 cycles) using a pool of all investigated self-
designed gene assays (primers) and ABI inventoried Taqman® 
gene expression assays (mixture of primers and fluorescence 
probes). The preamplified cDNA products were then diluted 
1:20 and subjected to real-time PCR analyses.
Table 5: Preamplification primers for SSRT-PreAmp
Gene 5' sense 3' primer 5' antisense 3' primer
HPRT-CCM GATATAATTGACACTGGCAAAAC ACAAACATGATTCAAATCCCTGA
CD3z CCGATTACAGAGGCACAGAG TCGTACTCCTCTCTTCGTCC
IFNg TTTTGGGTTCTCTTGGCTGTTA CTCTTTTGGATGCTCTGGTCA
FoxP3 CCCAGAGCTCCTACCCACT TGGCACTCAGCTTCTCCTTC
T-bet GACTGGAGGTGTCGGGGAA CCACGTCCACAAACATCCTG
GATA3 TCACAAAATGAACGGACAGAAC TAATATTGTGAAGCTTGTAGTAGA
Granulysin AGGAGCTGGGCCGTGACTA CTCTAGACTGATACCTCCTCA
Perforin TGTGGCCGGCTCACACTCA CGTAGTTGGAGATAAGCCTGA
Sequences of primers used for SSRT-PreAmp of the investigated 8 target genes.BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
Page 18 of 20
(page number not for citation purposes)
A ΔΔCt close to zero indicates ideal PreAmp uniformity.
ABI suggests a range between -1.5 to +1.5 PreAmp uni-
formity values as acceptable.
The coefficients of variation (CV) of the intra- and inter-
assay variance were calculated according to the formula
SD/meanx100.
To ascertain the possible impact of PCR efficiency on T-
PreAmp uniformity, cDNA from the pooled PBMCs was
diluted at 1:4, 1:16, 1:32, 1:64, 1:256, 1:512 and 1:1,024.
PCR efficiency was calculated according to the formula: -
1+10(-1/slope). The data from direct and from T-PreAmp
real-time PCR on candidate (both self-designed and Taq-
man® ABI inventoried) gene assays with T-PreAmp uni-
formities ranging between -1.5 and +1.5 (HPRT-CCM,
CD3d, CD3z, TRBC, TRBV19, TRBV29, NFATC3 and
av5b1), as well as on the 2 gene assays showing T-PreAmp
uniformities out of this range (HPRT-ABI and CD56) were
compared.
Statistical analysis
Statistical analysis was performed using JMP Statistical
Discovery Software V5.1.2 (SAS Institute, Inc., Cary, NC,
USA). Data are expressed as means ± standard deviation
(SD). We compared ordinal with continuous data
employing the student's t-test. Continuous data were
compared using the Spearman ρ test. A probability value
of p < 0.05 was considered statistically significant.
Commonly used abbreviations
For the list of abbreviations commonly used in the manu-
script see Additional File 3.
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SSRT-PreAmp procedure Figure 13
SSRT-PreAmp procedure. Principle of the SSRT-PreAmp 
technique: Isolated RNA was reverse transcribed to cDNA 
using a sequence specific 3'primer for each gene of interest 
(white box). Generated cDNA was preamplified (10 cycles) 
in a multiplex PCR by using the specific 3'primer of cDNA-
synthesis and a specific 5'primer (light grey box). Next, prod-
ucts of the first PCR round were split into individual wells 
and amplified separately in real-time PCR applying nested 
amplification primers (dark grey boxes).BMC Molecular Biology 2008, 9:3 http://www.biomedcentral.com/1471-2199/9/3
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